Electra Therapeutics, Inc. (ETRA)
Nasdaq · Healthcare · Biotechnology
$9.74−6.08%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $611M
- 52-week range
- $9.28 – $15.50
- 52-week change
- −21.74%
- EPS (trailing)
- −$2.49
About Electra Therapeutics, Inc.
Electra Therapeutics, Inc. is a clinical-stage biotechnology company. It develops therapies that target signal regulatory proteins for the treatment of novel targets for diseases in immunology and cancer. Its product, ELA026, is a monoclonal antibody that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, enabling medical professionals to find an approved treatment for secondary hemophagocytic lymphohistiocytosis, a life-threatening hyperinflammatory condition. The company was incorporated in 2018 and is based in South San Francisco, California.
Headquarters: South San Francisco, United States · 46 employees · electra-therapeutics.com